Introduction
Chronic obstructive pulmonary disease, or COPD, is a long-term lung disease that makes difficult to breathe. It can develop gradually that some people may miss early symptoms like persistent coughing or breathlessness until these symptoms start to interfere with everyday activities.
COPD is the third leading cause of morbidity and mortality in the world. The Global Burden of Disease study estimated a total of 384 million prevalent cases worldwide in 2010, constituting approximately 11.7% of the world’s population. By 2015, the World Health Organization (WHO) estimated that 174 million people were affected and 3.2 million died annually. The prevalence is expected to increase in the next few decades due to continued global tobacco use and ageing populations.
Early diagnosis, proper medical management, avoidance of respiratory irritants, physical activity, pulmonary rehabilitation and healthy lifestyle choices are helpful in managing symptoms and improving quality of life.
Understanding the symptoms, causes, risk factors and prevention of COPD can help people to know when to get a medical assessment and how to protect their long-term respiratory health.
What is COPD?
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease characterised by persistent and progressive airflow limitation that is usually caused by significant exposure to noxious particles or gases and is caused by airway or alveolar abnormalities. The airflow limitation results from a mixture of small airway disease (obstructive bronchiolitis) and destruction of the parenchyma (emphysema), with the relative contribution of each varying from individual to individual.
COPD is a systemic disease with extrapulmonary manifestations, independent prognostic factors, including skeletal muscle dysfunction, cardiovascular disease, metabolic syndrome, osteoporosis, depression, anxiety and anaemia. Clinically, the disease is characterised by chronic dyspnoea, cough and sputum production. However, the clinical spectrum ranges from completely asymptomatic patients with spirometric obstruction to patients with severe respiratory failure requiring mechanical ventilation. [1]
Types of COPD
COPD is not always classified into discrete disease types. Instead, health care providers may describe the primary forms of lung damage as chronic bronchitis and emphysema.
Chronic Bronchitis
Chronic bronchitis is characterised by inflammation of the bronchial airways and increased mucus production. Persistent cough with phlegm is a common complaint. It can be caused by repeated exposure to tobacco smoke, air pollution, dust, fumes and other airway irritants.
Lung Emphysema
Emphysema is damage to the walls of the alveoli (tiny air sacs in the lungs where oxygen passes into the blood and carbon dioxide is taken out). Damage to these structures reduces the efficiency of the lungs in gas exchange and may cause breathing to become increasingly difficult.
Mixed Features
Many patients with COPD have features of both chronic bronchitis and emphysema. Symptoms and severity can vary widely from person to person and therefore treatment is individualised based on symptoms, lung function and exacerbation history.
Common Symptoms of COPD
There are various symptoms of COPD, but the cardinal symptoms of COPD include:
-
Dyspnoea: Difficulty in breathing or panting.
-
Chronic cough: Cough is often the first symptom and may be either productive or non-productive. Chronic cough is clinically defined as a productive cough that occurs on most days for at least 3 months in each of 2 consecutive years.
-
Sputum production: Too much mucus or phlegm is made.
-
Wheezing and chest tightness: This is seen in a variable subset, especially during exacerbations and in the asthma-COPD overlap phenotype.
-
Fatigue, unintentional weight loss and anorexia: These are systemic features of advanced COPD, each independently associated with worse prognosis.
Causes or Risk Factors of COPD
COPD is the result of gene-environment interactions throughout a life. In high-income countries, cigarette smoking is responsible for about 70% to 80% of cases. However, 25% to 45% of patients with COPD have never smoked, highlighting the relevance of non-tobacco etiologies including biomass fuel combustion, occupational exposures, and host genetic factors. 
Environmental and Occupational Risk Factors
-
Tobacco smoking: It is the leading reason in high-income countries. Risk correlates with pack-year history and age of starting. Pipe, cigar, hookah and marijuana smoke also confer independent risk.
-
Biomass fuel combustion: The use of wood, crop residues and animal dung in indoor, poorly ventilated spaces is the main global risk factor for COPD, particularly in resource-limited countries.
-
Occupational exposures: COPD occurs independently in non-smokers due to coal dust, crystalline silica, cadmium, isocyanates, and organic dusts. Mining, farming, construction and textile work are high-risk occupations.
-
Respiratory infections: A history of severe lower respiratory tract infection in childhood, recurrent pneumonia, and previous pulmonary tuberculosis impair lung development and increase lifetime susceptibility to COPD. [2]
Host Factors
Apart from the environmental and occupational risk factors, there are various host factors that are responsible for the cause of COPD. Those factors include:
-
α-1 Antitrypsin deficiency (AATD)
-
Abnormal lung development
-
Asthma and airway hyper-responsiveness
-
Genetic predisposition and exacerbated lung ageing
Diagnosis of COPD
Chronic Obstructive Pulmonary Disease (COPD) is diagnosed primarily by the presence of persistent airflow limitation on spirometry, along with compatible symptoms and risk factors. Various assessment parameters that are involved in diagnosis of COPD are:
Clinical Suspicion
COPD should be suspected especially in >40-year-olds with respiratory symptoms having relevant risk factors. The history should evaluate:
-
Tobacco/smoking exposure and pack-years
-
Occupational / Environmental Exposures
-
Exposure to biomass fuel
-
Previous respiratory infections or tuberculosis
-
History of exacerbations
-
Inhaler use and adherence
-
Co-morbidities & functional limitations
Confirmatory Diagnostic Test- Spirometry
Spirometry is the main test used to diagnose COPD. It measures how much air a person can breathe out and how quickly they exhale.
In spirometry, a person inhales deeply and then exhales as forcefully as they can into a device called a spirometer.
The results can assist healthcare professionals in assessing airflow limitation, and in distinguishing COPD from other conditions that may present with similar symptoms.
Other Diagnostic Tests
Depending on the individual's symptoms and clinical situation, additional tests may include:
-
Chest X-ray
-
CT scan
-
Other pulmonary function tests
-
Pulse oximetry
-
Arterial blood gas testing
-
Exercise testing
Treatment Option for the Management of COPD
Treatment of COPD is based on GOLD grade (1 to 4), GOLD group (A, B, E), blood eosinophil count, and the individual patient’s comorbidities, preferences, and functional status. Goals of therapy include symptom relief, prevention of exacerbations, slowing of disease progression, and decreased mortality. All patients require non-pharmacologic interventions; pharmacotherapy is individualized and escalated stepwise.
Non-Pharmacologic Interventions
-
Smoking Cessation: The most effective intervention to slow lung function decline and reduce mortality; combine pharmacotherapy with behavioural counselling.
-
Avoid Exposures: Reduce tobacco smoke, occupational dust/fumes, biomass fuel exposure, and air pollution.
-
Pulmonary Rehabilitation: It is recommended in patients with particular symptoms, and it improves dyspnoea, exercise capacity, quality of life and reduces hospital readmissions.
-
Long-term oxygen therapy: Indicated in patients with severe resting hypoxaemia such as cor pulmonale, polycythaemia or pulmonary hypertension.
-
Non-Invasive Ventilation (NIV): Consider long-term nocturnal NIV in stable hypercapnic COPD, especially after hypercapnic exacerbations.
-
Nutrition: Nutritional support is important in underweight patients, as low BMI is associated with increased mortality.
Pharmacologic Management
-
SABA/SAMA: Rescue therapy for acute symptoms.
-
LABA/LAMA: Preferred maintenance bronchodilators for stable COPD.
-
ICS: Add in patients with frequent exacerbations, asthma features, or high eosinophils; ICS monotherapy is not recommended.
-
Triple therapy (ICS/LABA/LAMA): For persistent exacerbations despite dual bronchodilation.
-
Roflumilast: For severe COPD with chronic bronchitis and frequent exacerbations.
-
Azithromycin: Consider in selected patients with frequent exacerbations.
-
Theophylline: A third-line option when inhaled therapies are unsuitable or insufficient.
-
Acute exacerbation: Intensified bronchodilators, short-course systemic corticosteroids, and antibiotics when indicated; oxygen/NIV for appropriately hospitalised patients.
Breathing Exercises and Pulmonary Rehabilitation
COPD can be helped by breathing exercises and pulmonary rehabilitation. These slow the rate of breathing, keep the airways open longer and remove trapped air or mucus.
Breathing Techniques
-
Pursed-Lip Breathing: Breathe in slowly through your nose for a count of 2. Purse your lips together like you are about to blow out a candle. Breathe out slowly through your mouth for a count of 4 (twice as long as the inhale). Use this when you are short of breath or climbing stairs.
-
Diaphragmatic (Belly) Breathing: Sit or lie comfortably, one hand on your chest and the other on your belly. Breathe slowly through your nose allowing your belly to rise, with your chest remaining still. Exhale slowly through pursed lips. Practice for 5 minutes, 2 to 3 times a day.
-
Huff Coughing: Take a slow, deep breath to fill your belly, hold for a few seconds, and use your stomach muscles to make a sharp "huff" sound (like fogging a mirror) to clear mucus without total exhaustion.
Role in Pulmonary Rehabilitation
-
Enhances Capacity: Consistent practice of breathing exercises with whole-body training can enhance functional exercise capacity and walking distance.
-
Reduces Panic: Techniques such as pursed-lip breathing give you a feeling of control when you suddenly feel breathless and slow a rapid breathing rate.
Herbal Support in the Management of COPD
Herbal support can serve as a complementary approach in the management of COPD, especially for symptom relief and overall respiratory wellness. Classical herbs such as Adhatoda vasica (Vasa), Glycyrrhiza glabra (Mulethi), Piper longum (Pippali), Ocimum sanctum (Tulsi) and Emblica officinalis (Amla) have been traditionally used to support respiratory function, soothe the airways and provide antioxidant effects. However, herbal preparations should be used as an adjunct to, not in place of, evidence-based COPD treatment and the safety and potential interactions with prescribed medicines should be taken into account.
|
S. No. |
Herb / Ingredient |
Potential role in COPD |
Clinical reference |
|
1 |
Panax ginseng (Ginseng) |
Studied for lung function, exercise capacity and respiratory health. Earlier RCTs reported improvements in pulmonary function and exercise capacity, although later larger trials did not demonstrate significant benefit on quality of life or exacerbations. |
Celli et al.; Respiratory Medicine / PubMed PMID: 12814035; ACTRN12610000768099 |
|
2 |
Panax notoginseng saponins |
May support lung function, oxygenation and blood-rheology parameters, particularly in COPD patients with hypercoagulability. |
Zhou et al., Phytomedicine, 2024; PMID: 38216446; DOI: 10.1016/j.phymed.2023.155244 |
|
3 |
Astragalus membranaceus (Astragalus) |
Used in several Chinese herbal formulations studied as an adjunct to conventional COPD therapy; studies have reported potential benefits in exercise capacity and BODE-related outcomes. |
Guo et al., systematic review; PubMed PMID: 24622390 |
|
4 |
Cordyceps sinensis |
Included in multi-herbal COPD interventions; investigated for respiratory function, exercise capacity and overall COPD symptom support. |
Guo et al., systematic review; PubMed PMID: 24622390 |
|
5 |
Chinese herbal medicine combinations |
As an adjunct to conventional therapy, clinical trials/meta-analyses report improvements in CAT/SGRQ scores and, in some analyses, reduction in exacerbation frequency. |
Xiong et al., Complementary Therapies in Medicine, 2021; PMID: 33618010 |
|
6 |
Chinese herbal oral pastes/formulations |
Adjunctive use has been associated with improvements in symptoms, quality of life, lung function and 6-minute walk distance in some RCTs, although study quality and heterogeneity remain concerns. |
Zeng et al., systematic review/meta-analysis, 2020; PMID: 32308709 |
Herbal formulations may provide complementary support for respiratory wellness in individuals experiencing symptoms such as cough, mucus accumulation, chest congestion and airway irritation. Ethniq Respi Revive Avaleha and Lung Detox Tea combine traditionally used herbs such as Vasa, Mulethi, Pippali, Tulsi and other botanicals to support mucus clearance, soothe airway irritation and promote easier breathing. The products can be incorporated as part of a daily respiratory-wellness routine, particularly alongside healthy lifestyle measures and avoidance of respiratory irritants such as tobacco smoke and air pollution.
Conclusion
COPD is a chronic, progressive lung disease that can impact your breathing, activity level and quality of life. Recognising symptoms such as persistent cough, sputum production, breathlessness and wheezing, particularly in those with relevant risk factors, may help to encourage prompt medical assessment.
COPD is not reversible, but early diagnosis, smoking cessation, avoiding respiratory irritants, proper medical treatment, pulmonary rehabilitation, regular physical activity, and healthy lifestyle practices can help control symptoms and reduce the risk of exacerbations. Spirometry is still the key test for confirming persistent airflow limitation.
Breathing exercises such as pursed-lip breathing, diaphragmatic breathing and huff coughing, as part of a wider respiratory-health plan, can also help to control breathing and clear mucus.
Hence, a holistic strategy involving risk-factor reduction, medical care, lifestyle management and appropriate rehabilitation is required to maintain respiratory health. Any individual with persistent or worsening respiratory symptoms should be evaluated by a qualified health care professional.
Frequently Asked Questions (FAQs)
1. What is COPD?
COPD or chronic obstructive pulmonary disease is a chronic lung disease that causes a persistent limitation of airflow. It often has features of chronic bronchitis, emphysema or both, and can lead to breathlessness, chronic cough and sputum production.
2. What are the signs and symptoms of COPD?
Common symptoms are shortness of breath, persistent cough, sputum production, wheezing and chest tightness. In more advanced disease, fatigue, loss of appetite and weight loss without trying may also happen.
3. What are the major risk factors for COPD?
Tobacco smoking is a major risk factor but people who have never smoked can also develop COPD. Other risks are exposure to biomass fuels, occupational dust and fumes, air pollution, recurrent respiratory infections and some genetic factors like alpha-1 antitrypsin deficiency.
4. How is COPD diagnosed?
The diagnosis of COPD is based on postbronchodilator spirometry, compatible symptoms and relevant risk factors. An FEV₁/FVC ratio < 0.70 after bronchodilator administration indicates persistent airflow limitation consistent with COPD.
5. Is COPD a curable disease?
Yes, Management may include smoking cessation, avoidance of respiratory irritants, pulmonary rehabilitation, appropriate inhaled medications, physical activity, nutritional support and other treatments according to disease severity and individual needs. Treatment is adjusted to suit the symptoms, lung function, history of exacerbations and other factors.
6. Will breathing exercises help those with COPD?
Breathing exercises can be included in the management of COPD and pulmonary rehabilitation. Pursed lip breathing, diaphragmatic breathing and huff coughing can help with breath control, reducing breathlessness and clearing mucus.
Abbreviations Used:
|
S. No. |
Abbreviation |
Full Form |
|
1 |
COPD |
Chronic Obstructive Pulmonary Disease |
|
2 |
WHO |
World Health Organization |
|
3 |
AATD |
Alpha-1 Antitrypsin Deficiency |
|
4 |
FEV₁ |
Forced Expiratory Volume in the First Second |
|
5 |
FVC |
Forced Vital Capacity |
|
6 |
GOLD |
Global Initiative for Chronic Obstructive Lung Disease |
|
7 |
CAT |
COPD Assessment Test |
|
8 |
SABA |
Short-Acting Beta₂-Agonist |
|
9 |
SAMA |
Short-Acting Muscarinic Antagonist |
|
10 |
LABA |
Long-Acting Beta₂-Agonist |
|
11 |
LAMA |
Long-Acting Muscarinic Antagonist |
|
12 |
ICS |
Inhaled Corticosteroid |
|
13 |
NIV |
Non-Invasive Ventilation |
|
14 |
PaO₂ |
Partial Pressure of Arterial Oxygen |
|
15 |
SpO₂ |
Peripheral Oxygen Saturation |
|
16 |
BMI |
Body Mass Index |
|
17 |
Pi*ZZ |
Pi-ZZ Alpha-1 Antitrypsin Genotype |
References:
-
Kanchustambham V, Brown BD. Chronic Obstructive Pulmonary Disease (COPD) [Updated 2026 Apr 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559281/
-
Kanchustambham V, Brown BD. Chronic Obstructive Pulmonary Disease (COPD) [Updated 2026 Apr 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559281/
